Illumina Announces LIFE & BRAIN as Germany's First Certified Genetic Analysis Service Provider
News Jun 23, 2008
Illumina, Inc. has announced that LIFE & BRAIN is the first company in Germany to become an Illumina CSPro® (certified service provider). Illumina CSPro is a collaborative service provider partnership dedicated to ensuring the delivery of quality data available for genetic analysis applications.
LIFE & BRAIN offers its customers whole-genome genotyping services using Illumina's Infinium® Assay. The Infinium HD (High-Density) product line provides researchers with the ability to perform large-scale interrogation of the human genome to cost-effectively fast forward their research and identify genetic variants linked to disease.
"Our mission is to delineate the molecular pathogenesis of common diseases and to develop specific diagnostic and therapeutic tools," said Sven Cichon, Ph.D., Head of the Molecular Genetics Laboratory at LIFE & BRAIN. "By becoming an Illumina CSPro, we are demonstrating our commitment to our customers by offering them access to the highest quality genetic analysis services."
Illumina CSPro participants undergo a rigorous two-phase certification process that includes minimum data generation, data certification, and an on-site audit of the facility and processes.
"Interest in the Illumina CSPro program continues to grow with almost 20 academic and commercial technology providers already certified or in the process of certification. Now that LIFE & BRAIN is a partner, we are excited to work with them to make it easier for researchers in Germany to access the power of Illumina's genetic analysis technologies," said Karen Possemato, Director of Corporate Marketing at Illumina.
Mechanism Controlling Multiple Sclerosis Risk IdentifiedNews
Researchers at Karolinska Institutet have now discovered a new mechanism of a major risk gene for multiple sclerosis (MS) that triggers disease through so-called epigenetic regulation. They also found a protective genetic variant that reduces the risk for MS through the same mechanism.
Synthetic DNA Shuffling Enzyme Outpaces Natural CounterpartNews
A new synthetic enzyme, crafted from DNA rather than protein, flips lipid molecules within the cell membrane, triggering a signal pathway that could be harnessed to induce cell death in cancer cells. Researchers say their lipid-scrambling DNA enzyme is the first in its class to outperform naturally occurring enzymes – and does so by three orders of magnitudeREAD MORE
Antarctic Worm and Machine Learning Help Identify Cerebral Palsy EarlierNews
A research team has released a study in the peer-reviewed journal BMC Bioinformatics showing that DNA methylation patterns in circulating blood cells can be used to help identify spastic cerebral palsy (CP) patients. The technique which makes use of machine learning, data science and even analysis of Antarctic worms, raises hopes for earlier targeted CP therapies.